Company profile

ProKidney Corp.

Pipeline1 asset

RilparencelREACT

Latest news4 items

Oct 2, 2026

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria

Presentation / Abstract • Phase 2Phase 2 pooled analysis poster at ASN Kidney Week Fri, Oct 23, 2026, 10:00 AM MDT

Aug 10, 2026

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth

Enrollment • Phase 3Enrollment milestone Tue, Jun 30, 2026

Jun 2, 2026

ProKidney Appoints Kenneth Locke as Chief Technical Officer

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) --

May 15, 2026

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology

Enrollment • Phase 3Enrollment completion Tue, Jun 30, 2026